Ankit Vora, Group Project Director at Messe Muenchen India Pvt Ltd, is a strategic force behind India’s leading trade fairs in the pharmaceutical and analytical technology sectors. With over a decade of experience in exhibition design, commercial partnerships, and industry engagement, he has played a pivotal role in transforming platforms like analytica Lab India and Pharma Pro&Pack Expo into high-impact business accelerators. Known for his ability to align global innovation with domestic market needs, Vora brings a sharp focus on technology adoption, sustainability, and commercial ROI—making him a key voice in shaping the future of India’s pharma exhibition landscape.
In this exclusive conversation with Rashmi Kumari of Neo Science Hub, Vora outlines how the exhibition catalyzed real sales, strategic partnerships, and future-ready thematic evolution.
With this year’s edition achieving a visitor surge and growth in new exhibitors compared to previous editions, what specific commercial outcomes and business partnerships have emerged from the three-day event, and how do you quantify the exhibition’s success in terms of actual technology adoption, equipment sales conversions, and long-term collaborations between exhibitors and the pharmaceutical industry participants?
We measure success by tracking three layers of impact. First, short-cycle sales conversions—exhibitors have reported confirmed orders for advanced analytical instruments, process equipment, and automation solutions directly linked to interactions during the fair. Second, adoption pipelines—several pharma and biotech companies, along with a growing number of startups and MSMEs, have initiated pilot deployments and signed strategic MoUs with equipment manufacturers to integrate advanced technologies and software systems into their existing or upcoming facilities. Third, and most strategically, the trade fairs catalysed multi-year collaboration frameworks that connect global suppliers with Indian pharmaceutical producers, CROs, and research institutions. Collectively, these outcomes underscore that analytica Lab India and Pharma Pro&Pack Expo have evolved into a commercial accelerator and technology adoption catalyst for the broader pharmaceutical and allied manufacturing ecosystem.
Given the demonstrated industry emphasis on sustainability initiatives, digital transformation, and regulatory compliance challenges showcased during the conference sessions—from Zero Loss Philosophy to green laboratory implementations—how will you strategically evolve the exhibition format and content focus for future editions to address the clear industry shift toward AI-driven analytics, environmental sustainability, and advanced manufacturing technologies while maintaining commercial viability for both international and domestic participants?
Our roadmap for future editions is built around deepening thematic relevance while safeguarding commercial ROI. We intend to expand dedicated pavilions for AI-driven analytics, robotics, and sustainable lab practices, paired with application-focused live demonstrations where buyers can experience technologies in operation rather than in static displays. On the content side, conferences will evolve toward case-led sessions on regulatory technologies, zero-loss manufacturing, and carbon-neutral labs to reflect the industry’s sustainability agenda.
To maintain commercial viability for both global and domestic participants, we are strengthening the Hosted Buyer Program with segmented tracks—ensuring that international suppliers can access scale-driven Indian markets. In contrast, domestic innovators find new export pathways and regional partnerships. In essence, the trade fairs will evolve into a technology-to-market platform that aligns with the pharma sector’s digital and green transformation while driving measurable business outcomes.
